Qube Research & Technologies (QRT)
MRSN

Qube Research & Technologies (QRT)’s Mersana Therapeutics MRSN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,115
Closed -$45.3K – 3826
2025
Q2 		$45.3K Sell
6,115
-40,869
-87% -$359K ﹤0.01% 3164
2025
Q1 		$404K Buy
46,984
+33,087
+238% +$511K ﹤0.01% 2624
2024
Q4 		$497K Sell
13,897
-21,185
-60% -$1.1M ﹤0.01% 2479
2024
Q3 		$1.66M Sell
35,082
-4,621
-12% -$204K ﹤0.01% 1827
2024
Q2 		$2M Buy
39,703
+1,315
+3% +$95.1K ﹤0.01% 1626
2024
Q1 		$4.3M Buy
+38,388
New +$3.82M 0.01% 1325
2023
Q3 		– Sell
-8,164
Closed -$672K – 4248
2023
Q2 		$672K Sell
8,164
-1,908
-19% -$279K ﹤0.01% 1438
2023
Q1 		$1.03M Buy
10,072
+6,617
+192% +$929K ﹤0.01% 1278
2022
Q4 		$506K Buy
3,455
+1,251
+57% +$211K ﹤0.01% 1469
2022
Q3 		$372K Buy
2,204
+1,279
+138% +$208K ﹤0.01% 1562
2022
Q2 		$107K Sell
925
-11,053
-92% -$1.04M ﹤0.01% 1928
2022
Q1 		$1.2M Buy
11,978
+9,668
+419% +$1.13M 0.01% 1075
2021
Q4 		$359K Buy
+2,310
New +$449K ﹤0.01% 1713
2021
Q3 		– Sell
-2,507
Closed -$851K – 2571
2021
Q2 		$851K Buy
+2,507
New +$949K 0.01% 1015

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT)'s MRSN Position: Q3 2025 in Review

Qube Research & Technologies (QRT) sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 6,115 shares — an estimated $45.3K sold.

Qube Research & Technologies (QRT) first reported a position in MRSN in Q2 2021 and held it in 14 quarters. The position peaked at $4.3M in Q1 2024. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Qube Research & Technologies (QRT) reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 6,115 Mersana Therapeutics shares in Q3 2025, an estimated $45.3K.
  • Qube Research & Technologies (QRT) first reported a position in Mersana Therapeutics in Q2 2021 and held it in 14 quarters.
  • Qube Research & Technologies (QRT)'s Mersana Therapeutics position peaked at $4.3M in Q1 2024.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2025, filed 14 Nov 2025.